Diabetic Dyslipidemia

Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

The leading cause of death in the United States is coronary artery disease. The diabetic patient has a two- to fourfold increased likelihood of coronary disease with two-thirds of patients with diabetes succumbing to their macrovascular disease and double the risk of dying of a myocardial infarction.

Keywords

Placebo Cholesterol Pancreatitis Metformin Cardiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steiner G. (2000) Lipid intervention trials in diabetes. Diabetes Care 23(Suppl 2):B49–B53.PubMedGoogle Scholar
  2. 2.
    Mykkanen L, Laakso M, Penttila I, Pyorala K. (1991). Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis 88:153–161.PubMedCrossRefGoogle Scholar
  3. 3.
    Best JD, O’Neal DN. (2000) Diabetic dyslipidemia, current treatment and recommendations. Drugs 59:1101–1111.PubMedCrossRefGoogle Scholar
  4. 4.
    Lamarche B, Tchernof A, Moorjani S, et al. (1997) Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95:69–75.PubMedGoogle Scholar
  5. 5.
    Steiner G. (2001) Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol 88:37N–40N.PubMedCrossRefGoogle Scholar
  6. 6.
    American Diabetes Association. (2000) Management of dyslipidemia in adults with diabetes. Diabetes Care 23(Suppl 1):S57–S60.Google Scholar
  7. 7.
    Goldberg IJ. (2001) Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 86:965–971.PubMedCrossRefGoogle Scholar
  8. 8.
    Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. (2001) Nonhypoghycemic effects of thiazolidinediones. Ann Intern Med 134:61–71.PubMedGoogle Scholar
  9. 9.
    Carwsell CI, Plosker GL, Jarvis B. (2002) Rosuvastatin. Drugs 62:2075–2085.CrossRefGoogle Scholar
  10. 10.
    Jones PH, Davidson MH, Stein EA, et al. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92:152–160.PubMedCrossRefGoogle Scholar
  11. 11.
    Capuzzi DM, Morgan JM, Carey CM, et al. (2004) Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol 7:176–181.PubMedCrossRefGoogle Scholar
  12. 12.
    The Scandinavian Simvastatin Survival Study. (1994) Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the 4S Study. Lancet 344:1383–1389.Google Scholar
  13. 13.
    Goldberg RB, Mellies MJ, Sacks FM, et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98:2513–2519.PubMedGoogle Scholar
  14. 14.
    The Diabetes Atherosclerosis Intervention Study. (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: a randomised study. Lancet 357:905–910.CrossRefGoogle Scholar
  15. 15.
    Despres JP. (2001) Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am J Cardiol 88:30N–36N.PubMedCrossRefGoogle Scholar
  16. 16.
    Rubins HB, Robins SJ, Collins D, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410–418.PubMedCrossRefGoogle Scholar
  17. 17.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349–1357.CrossRefGoogle Scholar
  18. 18.
    Downs JR, Clearfield M, Weis S, et al. (1998) Primary prevention fo acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615–1622.PubMedCrossRefGoogle Scholar
  19. 19.
    Heart Protection Study Collaborative Group. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22.CrossRefGoogle Scholar
  20. 20.
    Shek A, Ferrill M.J. (2001) Statin-fibrate combination therapy. Ann Pharmacother 35:908–917.PubMedCrossRefGoogle Scholar
  21. 21.
    Vrecer M, Turk S, Drinovec J, Mrhar A. (2003) Use of statins in primary and secondary prevention of coronary heart disease and ischemic strole. Meta-analysis of randomized trials. Int J Clin Pharmacol Ther 41:567–577.PubMedGoogle Scholar
  22. 22.
    Abbott Laboratories. (2001) Tricor Package Insert. North Chicago, IL.Google Scholar
  23. 23.
    Prucksaritanont T, Zhao JJ, Ma B., et al. (2002) Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042–1051.CrossRefGoogle Scholar
  24. 24.
    NCEP Expert Panel. (2001) Execuative Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497.CrossRefGoogle Scholar
  25. 25.
    Zhao XQ. (2002) Simvastatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome. Am Coll Cardiol 39(Suppl A):242A.CrossRefGoogle Scholar
  26. 26.
    Pan J, Lin M, Kesala RL, Van J, Charles MA. (2002) Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab 4:255–261.PubMedCrossRefGoogle Scholar
  27. 27.
    Garg A, Grundy SM. (1990) Nicotinic acid as therapy for dyslopidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723–726.PubMedCrossRefGoogle Scholar
  28. 28.
    The Coronary Drug Project Research Group. (1975) Clofibrate and niacin in coronary heart disease. JAMA 231:360–381.CrossRefGoogle Scholar
  29. 29.
    Canner PL, Berge KG, Wenger NK, et al. (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardio. 8:1245–1255.CrossRefGoogle Scholar
  30. 30.
    Carlson LA, Rosenhamer G. (1988) Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223:405–418.PubMedCrossRefGoogle Scholar
  31. 31.
    Canner PL, Furberg CD, McGovern ME. (2002) Niacin decreases of myocardial infarction and total mortality in patients with impaired fasting glucose or glucose intolerance: results from the Coronary Drug Project. Circulation 106(Suppl 1):S1–S16.Google Scholar
  32. 32.
    American Diabetes Association. (2000). Diabetes Care 23(Suppl 1):S1–S16.Google Scholar
  33. 33.
    Blankenhorn DH, Nessim SA, Johnson RL, et al. (1987) Beneficial effects of combined colestipolniacin therrapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257:3233–3240.PubMedCrossRefGoogle Scholar
  34. 34.
    Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. (1990) Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264:3013–3017.PubMedCrossRefGoogle Scholar
  35. 35.
    Brown BG, Brockenbrough A, Zhao XQ, et al. (1998) Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention fo death and myocardial infarciton: a 10-year familial atherosclerosis treatment study (FATS) follow-up [abstract 3341]. Circulation 98(Suppl I):I–635.Google Scholar
  36. 36.
    Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007–3012.PubMedCrossRefGoogle Scholar
  37. 37.
    Grundy SM, Vega GL, McGovern ME, et al. (2002) Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162:1568–1576.PubMedCrossRefGoogle Scholar
  38. 38.
    Elam MB, Hunninghake DB, Davis KB, et al. (2000) Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 284:1263–1270.PubMedCrossRefGoogle Scholar
  39. 39.
    Gagne C, Bays HE, Weiss SR, et al. (2002) Efficacy and safety of ezetimibe addded to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90:1084–1091.PubMedCrossRefGoogle Scholar
  40. 40.
    Zetia (Eletimibe). (2002) Annotated prescribing information: package insert. Merch/Schering Plough Pharmaceuticals Inc., North Wales.Google Scholar
  41. 41.
    American Diabetes Association. (2000) Management of dyslipidemia in adults with diabetes. Diabetes Care 23(Suppl 1):S57–S60.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations